Bispecific Antibodies Market - Global Industry Size, Share, Trends, Opportunity & Forecast, Segmented By Indication (Cancer, Inflammatory & Autoimmune Disorders, Others), By Region & Competition, 2021-2031F
The Global Bispecific Antibodies Market is projected to expand from USD 7.44 Billion in 2025 to USD 12.76 Billion by 2031, reflecting a compound annual growth rate of 9.41%. These therapeutics are engineered proteins capable of binding simultaneously to two distinct antigens or epitopes, offering novel mechanisms of action such as redirecting immune effector cells to tumor sites. This dual-targeting capability drives their increasing adoption in oncology and autoimmune disease treatments, supported by advances in protein engineering that surpass the limitations of monospecific options. The rapid commercial progression of this sector was highlighted by The Antibody Society, which noted that regulatory agencies in the United States and Europe granted first approvals to four bispecific antibodies in 2023.
However, the market faces substantial challenges regarding manufacturing complexity and production scalability. Synthesizing bispecific antibodies involves intricate processes to ensure correct chain pairing and stability, often resulting in lower yields and higher costs compared to conventional monoclonal antibodies. These technical hurdles make upscaling production difficult and necessitate stringent quality control measures. Such requirements can delay regulatory clearance and inflate the final cost of therapy, potentially impeding widespread market accessibility.
Market Driver
Strategic collaborations and licensing agreements within the biotechnology sector are fundamentally reshaping the landscape as pharmaceutical giants aggressively acquire external innovation to strengthen their immuno-oncology portfolios. Major players are mitigating early-stage development risks by purchasing established bispecific platforms capable of targeting multiple disease pathways simultaneously. This trend fosters an ecosystem where smaller biotechs receive essential capital while larger firms secure high-potential candidates for their pipelines. For example, according to Fierce Biotech, Merck entered a definitive agreement in January 2024 to acquire Harpoon Therapeutics for approximately $680 million to access its proprietary T-cell engager technology.
A surge in regulatory approvals for novel bispecific therapies further drives the market, validating the safety and efficacy of these complex modalities for broader patient populations. As manufacturing and clinical protocols standardize, regulatory bodies are accelerating authorizations, moving these treatments from experimental stages to mainstream practice. The Antibody Society noted that in 2024, agencies granted first approvals to several new bispecifics, including tarlatamab and zanidatamab. This regulatory success supports commercial viability, as evidenced by Roche?s report in October 2024 that sales of its bispecific medicine Vabysmo reached CHF 2.8 billion in the first nine months of the year.
Market Challenge
The complexity of manufacturing and production scalability remains a significant barrier to the expansion of the Global Bispecific Antibodies Market. Unlike standard monoclonal antibodies, bispecific formats require the precise engineering of two distinct binding arms, a process that inherently increases the risk of chain mispairing and product instability. These technical intricacies frequently result in lower production yields and higher levels of impurities, which directly escalate the cost of goods sold. Consequently, manufacturers face difficulties in upscaling processes to commercial levels, leading to high pricing structures that limit therapy accessibility and market penetration.
Moreover, these production hurdles necessitate stringent quality control measures that extend development timelines and delay regulatory decision-making. The rigorous scrutiny required to ensure the stability and safety of these complex molecules contributes to a high attrition rate during late-stage development. According to The Antibody Society, the overall approval success rates for antibody therapeutics in 2024 were estimated to range between 14% and 32%, reflecting the substantial developmental risks and regulatory hurdles that impede the rapid commercialization of such complex modalities and slow the market's growth trajectory.
Market Trends
The market is experiencing a definitive shift towards subcutaneous delivery formulations, driven by the need to enhance patient convenience and optimize healthcare resource utilization. Manufacturers are actively re-engineering intravenous therapies into subcutaneous formats to significantly reduce chair time and administration complexity, addressing the logistical burdens of chronic treatment regimens. This trend is supported by clinical evidence; according to Johnson & Johnson, data from the Phase 3 PALOMA-3 study in May 2024 demonstrated that the subcutaneous formulation of amivantamab reduced infusion-related reactions five-fold compared to the intravenous version while shortening administration time to approximately five minutes.
Concurrently, there is a major trend regarding the diversification of indications beyond oncology, as pharmaceutical developers pivot these modalities toward high-prevalence autoimmune disorders. While oncology remains a key area, the ability of bispecific antibodies to precisely deplete pathogenic B-cells or modulate dual inflammatory pathways has triggered increased investment in non-cancer applications such as atopic dermatitis and rheumatoid arthritis. This strategic expansion is exemplified by Merck & Co.?s agreement in August 2024 to acquire Curon Biopharmaceutical?s clinical-stage bispecific antibody CN201 for a potential $1.3 billion, explicitly aiming to leverage the asset for treating B-cell associated autoimmune diseases.
Key Market Players
In this report, the Global Bispecific Antibodies Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Company Profiles: Detailed analysis of the major companies present in the Global Bispecific Antibodies Market.
Available Customizations:
Global Bispecific Antibodies Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
However, the market faces substantial challenges regarding manufacturing complexity and production scalability. Synthesizing bispecific antibodies involves intricate processes to ensure correct chain pairing and stability, often resulting in lower yields and higher costs compared to conventional monoclonal antibodies. These technical hurdles make upscaling production difficult and necessitate stringent quality control measures. Such requirements can delay regulatory clearance and inflate the final cost of therapy, potentially impeding widespread market accessibility.
Market Driver
Strategic collaborations and licensing agreements within the biotechnology sector are fundamentally reshaping the landscape as pharmaceutical giants aggressively acquire external innovation to strengthen their immuno-oncology portfolios. Major players are mitigating early-stage development risks by purchasing established bispecific platforms capable of targeting multiple disease pathways simultaneously. This trend fosters an ecosystem where smaller biotechs receive essential capital while larger firms secure high-potential candidates for their pipelines. For example, according to Fierce Biotech, Merck entered a definitive agreement in January 2024 to acquire Harpoon Therapeutics for approximately $680 million to access its proprietary T-cell engager technology.
A surge in regulatory approvals for novel bispecific therapies further drives the market, validating the safety and efficacy of these complex modalities for broader patient populations. As manufacturing and clinical protocols standardize, regulatory bodies are accelerating authorizations, moving these treatments from experimental stages to mainstream practice. The Antibody Society noted that in 2024, agencies granted first approvals to several new bispecifics, including tarlatamab and zanidatamab. This regulatory success supports commercial viability, as evidenced by Roche?s report in October 2024 that sales of its bispecific medicine Vabysmo reached CHF 2.8 billion in the first nine months of the year.
Market Challenge
The complexity of manufacturing and production scalability remains a significant barrier to the expansion of the Global Bispecific Antibodies Market. Unlike standard monoclonal antibodies, bispecific formats require the precise engineering of two distinct binding arms, a process that inherently increases the risk of chain mispairing and product instability. These technical intricacies frequently result in lower production yields and higher levels of impurities, which directly escalate the cost of goods sold. Consequently, manufacturers face difficulties in upscaling processes to commercial levels, leading to high pricing structures that limit therapy accessibility and market penetration.
Moreover, these production hurdles necessitate stringent quality control measures that extend development timelines and delay regulatory decision-making. The rigorous scrutiny required to ensure the stability and safety of these complex molecules contributes to a high attrition rate during late-stage development. According to The Antibody Society, the overall approval success rates for antibody therapeutics in 2024 were estimated to range between 14% and 32%, reflecting the substantial developmental risks and regulatory hurdles that impede the rapid commercialization of such complex modalities and slow the market's growth trajectory.
Market Trends
The market is experiencing a definitive shift towards subcutaneous delivery formulations, driven by the need to enhance patient convenience and optimize healthcare resource utilization. Manufacturers are actively re-engineering intravenous therapies into subcutaneous formats to significantly reduce chair time and administration complexity, addressing the logistical burdens of chronic treatment regimens. This trend is supported by clinical evidence; according to Johnson & Johnson, data from the Phase 3 PALOMA-3 study in May 2024 demonstrated that the subcutaneous formulation of amivantamab reduced infusion-related reactions five-fold compared to the intravenous version while shortening administration time to approximately five minutes.
Concurrently, there is a major trend regarding the diversification of indications beyond oncology, as pharmaceutical developers pivot these modalities toward high-prevalence autoimmune disorders. While oncology remains a key area, the ability of bispecific antibodies to precisely deplete pathogenic B-cells or modulate dual inflammatory pathways has triggered increased investment in non-cancer applications such as atopic dermatitis and rheumatoid arthritis. This strategic expansion is exemplified by Merck & Co.?s agreement in August 2024 to acquire Curon Biopharmaceutical?s clinical-stage bispecific antibody CN201 for a potential $1.3 billion, explicitly aiming to leverage the asset for treating B-cell associated autoimmune diseases.
Key Market Players
- Amgen Inc
- F. Hoffmann-La Roche Ltd
- Genentech Inc
- Akeso Inc
- Johnson & Johnson Private Limited
- Taisho Pharmaceutical Co Ltd
- Immunocore Ltd
In this report, the Global Bispecific Antibodies Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
- Bispecific Antibodies Market, By Indication
- Cancer
- Inflammatory & Autoimmune Disorders
- Others
- Bispecific Antibodies Market, By Region
- North America
- United States
- Canada
- Mexico
- Europe
- France
- United Kingdom
- Italy
- Germany
- Spain
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- South America
- Brazil
- Argentina
- Colombia
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
Company Profiles: Detailed analysis of the major companies present in the Global Bispecific Antibodies Market.
Available Customizations:
Global Bispecific Antibodies Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
- Detailed analysis and profiling of additional market players (up to five).
1. PRODUCT OVERVIEW
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. RESEARCH METHODOLOGY
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. EXECUTIVE SUMMARY
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. VOICE OF CUSTOMER
5. GLOBAL BISPECIFIC ANTIBODIES MARKET OUTLOOK
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Indication (Cancer, Inflammatory & Autoimmune Disorders, Others)
5.2.2. By Region
5.2.3. By Company (2025)
5.3. Market Map
6. NORTH AMERICA BISPECIFIC ANTIBODIES MARKET OUTLOOK
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Indication
6.2.2. By Country
6.3. North America: Country Analysis
6.3.1. United States Bispecific Antibodies Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Indication
6.3.2. Canada Bispecific Antibodies Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Indication
6.3.3. Mexico Bispecific Antibodies Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Indication
7. EUROPE BISPECIFIC ANTIBODIES MARKET OUTLOOK
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Indication
7.2.2. By Country
7.3. Europe: Country Analysis
7.3.1. Germany Bispecific Antibodies Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Indication
7.3.2. France Bispecific Antibodies Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Indication
7.3.3. United Kingdom Bispecific Antibodies Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Indication
7.3.4. Italy Bispecific Antibodies Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Indication
7.3.5. Spain Bispecific Antibodies Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Indication
8. ASIA PACIFIC BISPECIFIC ANTIBODIES MARKET OUTLOOK
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Indication
8.2.2. By Country
8.3. Asia Pacific: Country Analysis
8.3.1. China Bispecific Antibodies Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Indication
8.3.2. India Bispecific Antibodies Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Indication
8.3.3. Japan Bispecific Antibodies Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Indication
8.3.4. South Korea Bispecific Antibodies Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Indication
8.3.5. Australia Bispecific Antibodies Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Indication
9. MIDDLE EAST & AFRICA BISPECIFIC ANTIBODIES MARKET OUTLOOK
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Indication
9.2.2. By Country
9.3. Middle East & Africa: Country Analysis
9.3.1. Saudi Arabia Bispecific Antibodies Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Indication
9.3.2. UAE Bispecific Antibodies Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Indication
9.3.3. South Africa Bispecific Antibodies Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Indication
10. SOUTH AMERICA BISPECIFIC ANTIBODIES MARKET OUTLOOK
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Indication
10.2.2. By Country
10.3. South America: Country Analysis
10.3.1. Brazil Bispecific Antibodies Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Indication
10.3.2. Colombia Bispecific Antibodies Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Indication
10.3.3. Argentina Bispecific Antibodies Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Indication
11. MARKET DYNAMICS
11.1. Drivers
11.2. Challenges
12. MARKET TRENDS & DEVELOPMENTS
12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments
13. GLOBAL BISPECIFIC ANTIBODIES MARKET: SWOT ANALYSIS
14. PORTER'S FIVE FORCES ANALYSIS
14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products
15. COMPETITIVE LANDSCAPE
15.1. Amgen Inc
15.1.1. Business Overview
15.1.2. Products & Services
15.1.3. Recent Developments
15.1.4. Key Personnel
15.1.5. SWOT Analysis
15.2. F. Hoffmann-La Roche Ltd
15.3. Genentech Inc
15.4. Akeso Inc
15.5. Johnson & Johnson Private Limited
15.6. Taisho Pharmaceutical Co Ltd
15.7. Immunocore Ltd
16. STRATEGIC RECOMMENDATIONS
17. ABOUT US & DISCLAIMER
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. RESEARCH METHODOLOGY
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. EXECUTIVE SUMMARY
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. VOICE OF CUSTOMER
5. GLOBAL BISPECIFIC ANTIBODIES MARKET OUTLOOK
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Indication (Cancer, Inflammatory & Autoimmune Disorders, Others)
5.2.2. By Region
5.2.3. By Company (2025)
5.3. Market Map
6. NORTH AMERICA BISPECIFIC ANTIBODIES MARKET OUTLOOK
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Indication
6.2.2. By Country
6.3. North America: Country Analysis
6.3.1. United States Bispecific Antibodies Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Indication
6.3.2. Canada Bispecific Antibodies Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Indication
6.3.3. Mexico Bispecific Antibodies Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Indication
7. EUROPE BISPECIFIC ANTIBODIES MARKET OUTLOOK
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Indication
7.2.2. By Country
7.3. Europe: Country Analysis
7.3.1. Germany Bispecific Antibodies Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Indication
7.3.2. France Bispecific Antibodies Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Indication
7.3.3. United Kingdom Bispecific Antibodies Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Indication
7.3.4. Italy Bispecific Antibodies Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Indication
7.3.5. Spain Bispecific Antibodies Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Indication
8. ASIA PACIFIC BISPECIFIC ANTIBODIES MARKET OUTLOOK
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Indication
8.2.2. By Country
8.3. Asia Pacific: Country Analysis
8.3.1. China Bispecific Antibodies Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Indication
8.3.2. India Bispecific Antibodies Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Indication
8.3.3. Japan Bispecific Antibodies Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Indication
8.3.4. South Korea Bispecific Antibodies Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Indication
8.3.5. Australia Bispecific Antibodies Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Indication
9. MIDDLE EAST & AFRICA BISPECIFIC ANTIBODIES MARKET OUTLOOK
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Indication
9.2.2. By Country
9.3. Middle East & Africa: Country Analysis
9.3.1. Saudi Arabia Bispecific Antibodies Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Indication
9.3.2. UAE Bispecific Antibodies Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Indication
9.3.3. South Africa Bispecific Antibodies Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Indication
10. SOUTH AMERICA BISPECIFIC ANTIBODIES MARKET OUTLOOK
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Indication
10.2.2. By Country
10.3. South America: Country Analysis
10.3.1. Brazil Bispecific Antibodies Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Indication
10.3.2. Colombia Bispecific Antibodies Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Indication
10.3.3. Argentina Bispecific Antibodies Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Indication
11. MARKET DYNAMICS
11.1. Drivers
11.2. Challenges
12. MARKET TRENDS & DEVELOPMENTS
12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments
13. GLOBAL BISPECIFIC ANTIBODIES MARKET: SWOT ANALYSIS
14. PORTER'S FIVE FORCES ANALYSIS
14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products
15. COMPETITIVE LANDSCAPE
15.1. Amgen Inc
15.1.1. Business Overview
15.1.2. Products & Services
15.1.3. Recent Developments
15.1.4. Key Personnel
15.1.5. SWOT Analysis
15.2. F. Hoffmann-La Roche Ltd
15.3. Genentech Inc
15.4. Akeso Inc
15.5. Johnson & Johnson Private Limited
15.6. Taisho Pharmaceutical Co Ltd
15.7. Immunocore Ltd
16. STRATEGIC RECOMMENDATIONS
17. ABOUT US & DISCLAIMER
